59748-90-2

Basic information

• Product Name: 4-Bromo-2-chlorobenzoic acid
• Synonyms: RARECHEM AL BO 2371;4-BROMO-2-CHLOROBENZOIC ACID;Benzoic acid, 4-bromo-2-chloro-;2-Chloro-4-bromobenzoic acid;4-BROMO-2-CHLOROBENZOIC ACID 98+%;2 - chloro - 4 - broMine benzoic acid;4-Bromo-2-chlorobenzoic acid 97%
• CAS NO: 59748-90-2
• Molecular Formula: C₇H₄BrClO₂
• Molecular Weight: 235.46
• EINECS: 261-911-9
• Product Categories: blocks;Bromides;Carboxes;Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Carboxylic Acids;Phenyls & Phenyl-Het;Highly Purified Reagents;Other Categories;Refined Products by Sublimation;Carboxylic Acids;Phenyls & Phenyl-Het;C7;Carbonyl Compounds;Benzoic acid series;Aromatics;Miscellaneous Reagents;Building Blocks;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks
• Mol File: 59748-90-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 171-175 °C
• Boiling Point: 319.1 °C at 760 mmHg
• Flash Point: 146.8 °C
• Appearance: /
• Density: 1.809 g/cm³
• Vapor Pressure: 0.000145mmHg at 25°C
• Refractive Index: 1.621
• Storage Temp.: Refrigerator
• Solubility: DMSO, Methanol
• PKA: 2.68±0.25(Predicted)
• CAS DataBase Reference: 4-Bromo-2-chlorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-2-chlorobenzoic acid(59748-90-2)
• EPA Substance Registry System: 4-Bromo-2-chlorobenzoic acid(59748-90-2)

Safety Data

• Hazard Codes: Xn,N,Xi
• Statements: 22-50/53
• Safety Statements: 60-61
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 59748-90-2(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

InChI:InChI=1/C7H4BrClO2/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3H,(H,10,11)

Upstream product

• 89794-02-5 4-bromo-2-chlorotoluene 
• 503555-23-5 tert-butyl 5-bromo-2-chloro-benzoate 
• 201230-82-2 carbon monoxide 
• 31928-47-9 4-bromo-2-chloroiodobenzene 
• 63468-61-1 C₇H₄ClN₂O₂⁽¹⁺⁾ 
• 2457-76-3 4-amino-2-chlorobenzoic acid 
• 119-32-4 4-Methyl-3-nitroanilin 

Downstream Products

• 682778-17-2 N,N-diethyl-4-bromo-2-chlorobenzamide 
• 850035-47-1 N,N-diethyl-2-chloro-4-ethylbenzamide 
• 850035-46-0 N,N-diethyl-2-chloro-4-ethenylbenzamide 
• 131994-22-4 ethyl 3-(4-bromo-2-chlorophenyl)-3-oxo-propionate 
• 131994-23-5 (Z)-2-(4-Bromo-2-chloro-benzoyl)-3-dimethylamino-acrylic acid ethyl ester 
• 131994-49-5 7-Bromo-1-(4-fluoro-phenyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 131994-50-8 7-Bromo-1-(4-fluoro-phenyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid amide 
• 131994-20-2 ethyl 7-bromo-1,4-dihydro-1-(4-fluorophenyl)-4-oxo-3-quinolinecarboxylate 
• 131994-26-8 ethyl 7-ethynyl-1,4-dihydro-1-(4-fluorophenyl)-4-oxo-3-quinolinecarboxylate 
• 131994-28-0 1,4-Dihydro-1-(4-fluorophenyl)-7-(3-methyl-5-isoxazolyl)-4-oxo-3-quinolinecarboxylic acid 
• 131994-24-6 ethyl 1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-<(trimethylsilyl)ethynyl>-3-quinolinecarboxylate 
• 131994-27-9 ethyl 1-(4-fluorophenyl)-1,4-dihydro-7-<5-(3-methylisoxazolyl)>-4-oxo-3-quinolinecarboxylate 
• 185312-82-7 4-bromo-2-chlorobenzoic acid methyl ester 
• 861605-94-9 2-phenoxy-4-bromobenzoic acid 

Relevant articles and documents

Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation

Transthyretin (TTR) is a homotetrameric protein. Its dissociation into monomers leads to the formation of fibrils that underlie human amyloidogenic diseases. The binding of small molecules to the thyroxin-binding sites in TTR stabilizes the homotetramer and attenuates TTR amyloidosis. Herein, we report on boronic acid-substituted stilbenes that limit TTR amyloidosis in vitro. Assays of affinity for TTR and inhibition of its tendency to form fibrils were coupled with X-ray crystallographic analysis of nine TTR·ligand complexes. The ensuing structure-function data led to a symmetrical diboronic acid that forms a boronic ester reversibly with serine 117. This diboronic acid inhibits fibril formation by both wild-type TTR and a common disease-related variant, V30M TTR, as effectively as does tafamidis, a small-molecule drug used to treat TTR-related amyloidosis in the clinic. These findings establish a new modality for covalent inhibition of fibril formation and illuminate a path for future optimization.

DEPROTECTION OF BOC-PROTECTED COMPOUNDS

Organic compounds having t-butyl ester or BOC carbonate protecting groups are effectively deprotected by heating in a fluorinated alcohol solution.

Tricyclic fused heterocycle compounds, process for preparing the same and use thereof

Compounds represented by formula (1), wherein X is, for example, CH, CH2, CHR (wherein R is a lower alkyl group or a substituted lower alkyl group) or CRR′ (wherein R and R′ are the same as the above defined R); Y is, for example, CH, CH2or C═O; Z is, for example, O, S, S=O or SO2; U is C or N; R1to R4are each independently, for example, a hydrogen atom, OR, SR (wherein R is the same as defined above), or an aromatic ring, a substituted aromatic ring or a heterocycle; at least one of R5and R8is, for example, OH and the remaining of R5and R8are each independently, for example, a hydrogen atom or OH, optical isomers thereof, conjugates thereof or pharmaceutically acceptable salts thereof are provided. These compounds are characterized in having a wide range of pharmacological actions such as an excellent relaxing action of tracheal smooth muscles, an inhibition of airway hypersensitivity and an inhibition of infiltration of inflammatory cells into the airway and, in addition, high safety.